Original Article
Salvianolic acid A attenuates early brain injury after subarachnoid hemorrhage in rats by regulating ERK/P38/Nrf2 signaling

Xiang Gu1, Chengzhang Zheng1, Qiaoying Zheng2, Shuiyu Chen1, Wei Li1, Zhanfang Shang1, Huabin Zhang1

Departments of 1Neurosurgery, 2Pharmacy Intravenous Admixture Services, Mindong Hospital Affiliated to Fujian Medical University, Fuan 355000, P. R. China

Received September 4, 2017; Accepted November 22, 2017; Epub December 15, 2017; Published December 30, 2017

Abstract: Oxidative stress and inflammation play an important role in the pathogenesis of early brain injury (EBI) following subarachnoid hemorrhage (SAH). The present study aimed to evaluate the effect of salvianolic acid A (SalA) on EBI after SAH via its antioxidative, anti-inflammatory, and anti-apoptotic effects. The intraperitoneal administration of SalA (10 and 50 mg/kg/day) significantly alleviated EBI (including neurobehavioral deficits, brain edema, blood-brain barrier permeability, and cortical neuron apoptosis) after SAH in rats. SalA treatment also reduced the post-SAH elevated levels of reactive oxygen species level and malondialdehyde. Further, SalA increased glutathione peroxidase enzymatic activity and the concentrations of glutathione and brain-derived neurotrophic factor in brain cortex, at 24 h after SAH. In addition, SalA also decreased the release of inflammation cytokines (i.e., TNF-α, IL-1β, IL-6, and IL-8) in SAH rats. Expressions of cell apoptosis-related proteins were also regulated by SalA treatment in SAH rats. Meanwhile, SalA also modulated Nrf2 signaling, and the phosphorylation of ERK and P38 MAPK signaling in SAH rats. These results indicated that the administration of SalA may ameliorate EBI and provide neuroprotection after SAH in rat models.

Keywords: Salvianolic acid A, subarachnoid hemorrhage, apoptosis, inflammatory cytokine, oxidative damage

Introduction
Subarachnoid hemorrhage (SAH) is a disease with high disability and mortality rate. The most common cause of SAH is ruptured cerebral aneurysm [1, 2]. Approximately 30% of patients die within the first few days, while 10% die in the following days due to various complications. The overall mortality rate is more than 50% [3]. SAH consists of 5-7% of total strokes and affects 10 per 100,000 adults each year. Most deaths occur in the early phase of initial bleeding, which results from the increased ICP or acute hydrocephalus [4]. SAH may induce early brain injury (EBI) and delayed brain injury, which can manifest as cerebral edema, intracranial hypertension, cerebral infarction, neurological disorders, and disturbances of consciousness. These symptoms may result from inflammation, cerebral vasospasm, apoptosis, etc. [5-7]. Currently, however, the specific pathogenesis and treatment strategy for SAH remains poorly understood and thus, warrants further study.

Salvianolic acid A (SalA) is one of the major active components of Salviae Miltiorrhizae Bunge (Danshen in Chinese). Extensive studies have demonstrated the potent protective effects of SalA against ischemia-induced injury both in vitro and in vivo [8, 9]. SalA reportedly attenuates inflammation, apoptosis, and oxidative stress, and decreases the expressions of AKT and NF-κB at the cellular level [10, 11]. However, there are only a few previous studies on the effects and molecular mechanisms of SalA on the blood-brain-barrier (BBB) and endogenous neurogenesis in ischemic stroke. The objective of the current study was to investigate the effects of SalA in EBI after SAH in rats. In particular, we aimed to elucidate whether treatment with SalA after SAH would protect...
SalA attenuates EBI after SAH in rats

Animal model

The protocols involving animal use in the current study were approved by the Institutional Animal Care and Use Committee of Mindong Hospital, which is affiliated with Fujian Medical University. Clean, adult male Sprague-Dawley rats, weighing 250-300 g, were obtained from Shanghai Laboratory Animal Center, Chinese Academy of Sciences. Animals were housed in a colony room under controlled temperature (22 °C), and a 12:12 light-dark cycle, with food and water available ad libitum. A rat model of SAH was induced by endovascular perforation, as described in a previous study [12], with minor modifications. Briefly, rats were anesthetized with an intraperitoneal injection of chloral hydrate (300 mg/kg). Then, the right common carotid artery, external carotid artery, and internal carotid artery (ICA) were carefully exposed through a ventral midline neck incision, and a blunted 3-0 monofilament nylon suture was inserted into the ICA, until resistance was felt (approximately 18-20 mm from the common carotid bifurcation). The suture was carefully pushed approximately 3 mm further to perforate the artery wall to create a SAH. Sham-operation rats were manipulated in the same manner without the perforation.

Experimental groups

Rats were divided into four groups as follows: (i) sham operation group, which underwent sham operation and received vehicle; (ii) SAH group, which was subjected to SAH and received vehicle; (iii) SalA 10 mg/kg group (SalA 10), which was subjected to SAH and treated with SalA 10 mg/kg; and (iv) SalA 50 mg/kg group (SalA 50), which was subjected to SAH and treated with SalA 50 mg/kg. For the vehicle control, the rats were treated with normal saline at the same volume as SalA. SalA (purity > 98%) was purchased from Shanghai Winherb Medical S & T Development Co., Ltd. (Shanghai, China).

Neurological scoring

Like in our previous study [13], behavioral activity was examined using three scoring systems (Table 1), at 48 h after SAH. Scoring was performed to record appetite, activity, and neurological deficits by two “blinded” investigators; the sequence of testing for the given tasks was randomized. Neurological deficits of the experimental animals were graded as follows: (i) no neurologic deficit (score = 0); (ii) suspicious or minimum neurologic deficit (score = 1); (iii) mild neurologic deficit (score = 2-3); and (iv), severe neurologic deficit (score = 4-6).

Assessment of brain edema

Rats were killed 24 h after SAH and the brains were extracted. Each rat brain was gently blotted with filter paper and weighed on an electronic balance to obtain the wet weight (WW). The brain tissue was then dried for 24 h, at 100 °C, in a vacuum oven, to obtain the dry weight (DW). The cerebral water content was calculated according to the following formulation: H2O (%) = (WW-DW)/WW × 100.

Measurement of BBB permeability

The Evans blue (EB) extravasation was measured to assess BBB permeability. EB dye (2% in saline) was injected into the left jugular vein 23 h after SAH. Thereafter, the rats were transcardially perfused with phosphate buffered saline (PBS) to remove the intravascular dye. The rat brains were then homogenized in a 10-fold volume of 50% trichloroacetic acid solution to precipitate protein and centrifuged for 10 min at 3000 r/min. The supernatant was diluted with ethanol (1:3) and its fluorescence was measured at 610 nm to measure the
SalA attenuates EBI after SAH in rats

Figure 1. (A) Schematic representation of the cortex sample area taken for the assay. Effect of salvianolic acid A (SalA) administration on (B-1) neurological scores, (B-2) brain water content of cerebral cortex, (B-3) Evans blue (EB) content as indices for BBB permeability, in the control group, subarachnoid hemorrhage (SAH), and SalA (10 and 50 mg/kg)-treated SAH groups. Values represented as mean ± standard deviation (n = 6, each group). **P<0.01 compared to control group; ***P<0.01 compared to SAH group.

Figure 1

absorbance of EB. The results were expressed as micrograms per gram tissue.

**TUNEL staining**

The terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling (TUNEL) assay was performed according to a previous study [14]. Rats were anesthetized 48 h after SAH and perfused transcardially with 0.9% saline, followed by 4% paraformaldehyde. Brains were removed and kept in 4% paraformaldehyde for 6 h, before being immersed in 30% sucrose for 3 days at 4°C. Brain sections (18 μm) were rinsed three times in PBS and blocked in 10% goat serum/PBS/0.1% Triton X-100 at room temperature for 2 h.

**Biochemical analysis**

Brain tissues were prepared in phosphate buffer (pH 7.4) to make 1:10 (w/v) homogenates. After centrifugation at 12,000 g for 20 min at 4°C, the supernatants were collected for biochemical analysis. The levels of malondialdehyde (MDA), glutathione (GSH), and glutathione peroxidase (GSH-Px) were determined using assay kits, which were purchased from Nanjing Jiancheng Biotech Ltd. (China). The values were normalized by the protein concentration of the sample, which was measured using a bicinchoninic acid (BCA) assay. The reactive oxygen species (ROS) level in the brain homogenates was measured using 2',7'-dichlorodihydrofluorescein diacetate (Sigma, USA), as outlined in a previous study [14].

**ELISA**

Frozen brain tissue (200 mg) was homogenized, at 24 h after the induction of SAH, with a plastic homogenizer in cell lysis buffer containing 1 mM phenylmethanesulfonylfluoride (PMSF), 20 mM Tris pH 7.5, 150 mM NaCl, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM EDTA, 1% Na3VO4, and 0.5 μg/ml leupeptin. Each sample was then centrifuged at 14,000 g for 20 min at 4°C. The cytokine contents (i.e., TNF-α, IL-1β, IL-6, and IL-8) in the brain tissue were measured using rat immunoassay enzyme-linked immunosorbent assay (ELISA) kits (Boster Biological Technology, LTD, Wuhan, China), according to the manufacturer’s instructions. The results were expressed as picograms per milliliter homogenate.

**Western blot**

Total protein was extracted from the brain samples using a protein extraction kit (Beyotime Biotech. Co., China) according to the manufac-
SalA attenuates EBI after SAH in rats

Figure 2. (A-1) Reactive oxygen species (ROS) production of cerebral cortex homogenate, (A-2) glutathione (GSH) concentration, (A-3) glutathione peroxidase (GSH-Px) activities, (A-4) malondialdehyde (MDA) concentration of cerebral cortex in the sham-operated group, vehicle-treated, or salvianolic acid A (SalA)-treated subarachnoid hemorrhage (SAH) group. (B) Inflammation cytokines (TNF-α, IL-1β, IL-6, and IL-8) were identified by ELISA. Values are represented as mean ± standard deviation (n = 6, each group). *P<0.05, **P<0.01 compared to sham-operated group; *P<0.05, **P<0.01 compared to SAH group.
turer’s instructions. Protein samples (50 μg) were separated using 10% SDS polyacrylamide gels and transferred to nitrocellulose membranes. The membranes were respectively incubated at 4°C for 2 h with a mouse monoclonal antibody against Nuclear factor E2 related factor 2 (Nrf2; 1:500, Abcam), HO-1 (1:200, Santa Cruz), NQO-1 (1:200, Santa Cruz), caspase-3 (1:500, Abcam), caspase-9 (1:500, Abcam), Bax (1:500, Abcam), Bcl-2 (1:500, Abcam), extracellular signal regulated kinases (ERK) 1/2 (1:500, Abcam), c-Jun N-terminal kinase (JNK) 1/2 (1:500, Abcam), p38 (1:500, Abcam), or GAPDH (1:500, Abcam). The nitrocellulose membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (1:3000, Zhongshan Biotechnology Co. LTD, Beijing) for 2 h at 25°C and developed with an enhanced chemiluminescence detection system. GAPDH was used as a loading control. The optical densities of protein bands were analyzed using Quantity One software (Bio-Rad).

Statistical analyses

Experimental data are presented as mean ± standard deviation (SD). Statistical analysis was performed using analysis of variance, followed by a Bonferroni test, for the individual comparisons between group means (SPSS 13.0 for Windows, USA). Statistical significance was set at P<0.05.

Results

Effect of SalA on neurological scores, brain edema, and BBB Permeability

When the rat brains were quickly removed 24 h after the SAH, subarachnoid blood clots were found on the ipsilateral side, around the circle of Willis, and within the ventral surface of the brain stem (Figure 1A). The neurological scores, which were significantly reduced at 24 h post-SAH, were significantly improved by the SalA (at 10 and 50 mg/kg) administration (P<0.01, Figure 1B-1). The elevation in the water content of the brain was elevated at 24 h post-SAH; this was attenuated by SalA (10 and 50 mg/kg; P<0.01, Figure 1B-2). Further, the obvious increase in EB content at 24 h post-SAH, was also significantly attenuated by the administration of SalA (10 and 50 mg/kg; P<0.01, Figure 1B-3).
SalA attenuates EBI after SAH in rats

24 h post-SAH, compared to the control group, the ROS level of brain cortex homogenate was significantly increased in the vehicle-treated SAH group. However, compared with the vehicle-treated SAH group, the administration of SalA (10 and 50 mg/kg) significantly decreased the production of ROS in the brain cortex (P<0.01, Figure 2A-1). Further, the SAH significantly decreased the GSH concentration and GSH-Px enzyme activity in brain cortex, compared to that in the control group at 24 h. The GSH concentration and GSH-Px enzyme activity in the SalA (10 and 50 mg/kg)-treated
SalA attenuates EBI after SAH in rats

SAH groups, however, were significantly increased compared with the vehicle-treated SAH group, at 24 h (P<0.05, Figure 2A-2 and 2A-3). Further, SAH significantly increased the concentration of MDA, i.e., an oxidative damage marker of lipids, in brain cortex, compared to the control group at 24 h. SalA (10 and 50 mg/kg) treatment, however, significantly reversed this increase (P<0.05, Figure 2A-4).

Moreover, compared with the rats in the sham-operation group, the SAH increased the expression of inflammatory cytokines (i.e., TNF-α, IL-1β, IL-6, and IL-8) in the rat brain (P<0.01). SalA (10 and 50 mg/kg) significantly downregulated the release of TNF-α, IL-1β, IL-6 and IL-8 in rats with a SAH (P<0.05, Figure 2B).

Inhibition of cortical apoptosis after SAH by SalA

We assessed the brain cortex in each group using TUNEL to determine whether SalA prevents cortical apoptosis. Compared with the sham-operated group, numerous TUNEL-positive cells were observed in brain cortex of rats in the vehicle-treated SAH group (Figure 3). However, SalA treatment (10 and 50 mg/kg) significantly reduced the increase in TUNEL-positive cells in the rats in the SalA-treated SAH groups, compared with that in the vehicle-treated SAH group (Figure 3).

Effect of SalA on the expression of apoptosis-related proteins and Nrf2 signaling

The protein expression of caspase-3, caspase-9, and Bax/Bcl-2 was measured using western blot analysis. As shown in Figure 4A, a steep increase in the activities of caspase-3 and caspase-9 was observed in the brain cortex of rats that underwent a SAH. The increased activation of caspase-9 indicated that a SAH can initiate apoptosis, mediated by mitochondria and/or death receptors. However, the SalA (10 and 50 μM) treatment dramatically suppressed the activation of caspase-3 and caspase-9 induced by SAH, in a dose-dependent manner. In addition, compared to the control, the SAH also notably increased the expression of Bax/Bcl-2 (Figure 4A). The SalA (10 and 50 μM), however, suppressed this increase. In conclusion, the results demonstrated that SalA was an effective inhibitor of SAH-induced apoptosis in the brain cortex of rats. The decreased expression of Nrf2 and its downstream targets (HO-1 and NQO-1) in rats that underwent a SAH, was significantly mitigated with SalA (10 and 50 μM) treatment (Figure 4B).

Effect of SalA on mitogen-activated protein kinase (MAPK) signaling

Next, we used a western blot to detect the protective effect of SalA on the phosphorylation of ERK1/2, P38, and JNK1/2, to determine the protective effect of SalA against oxidative damage via MAPK signaling. As shown in Figure 4C, the SAH increased the phosphorylation of P38 MAPK and decreased the phosphorylation of ERK; these changes were reversed by the SalA treatment. Although the phosphorylation of JNK was also increased in the SAH group, the SalA treatment had no effect on the phosphorylation of JNK.

Discussion

The current study demonstrated that the intraperitoneal administration of SalA (10 and 50 mg/kg/day) was protective for EBI following SAH, at least partly through its antioxidative, anti-inflammatory, and antiapoptotic effects. The evidence that led to this conclusion is as follows: SalA significantly improved neurological deficits, ameliorated brain edema and BBB permeability, inhibited inflammation factors, and suppressed oxidative stress and cortical neuron apoptosis, at 48 h after a SAH in a rat model. Further, SalA significantly decreased the SAH-induced formation of MDA and ROS, and increased the GSH concentration and GSH-Px activities. These findings suggested that treatment with SalA may provide an effective method for protecting the brain against EBI following SAH in rats.

The key pathological processes that underlie EBI after SAH include neuron cell necrosis, BBB damage, and brain edema [15]. These pathological processes significantly contribute to the inflammatory reaction and oxidative stress of the pressure, which forms after a SAH. The increase in ROS in EBI after SAH can cause neuronal necrosis and destroy the BBB. The destruction of the BBB and inflammation tends to cause vasogenic cerebral edema, which ultimately leads to neurological deterioration. The increased pressure due to brain edema is one of the primary reasons for neurological deterio-
SalA attenuates EBI after SAH in rats

The MDA content, which reflects lipid peroxidation [16, 17], was significantly increased by the SAH in rats. This was indicative of the presence of oxidative stress damage due to SAH. Our results demonstrated that SalA reduced the content of MDA in rat model of SAH. Thus, the potential neuroprotective effect of SalA may be, at least partially, related to its inhibition of oxidative stress. Nrf2 plays a role in regulating antioxidants during EBI after a SAH [18, 19]. The activation of Nrf2 signaling pathways activate the antioxidant signaling pathway to reduce the oxidative stress effect of brain tissue and BBB during EBI [20]. SalA activates the Nrf2 signaling pathway to reduce the pressure of liver oxidative stress [21-23]. In the current study, the expression of Nrf2 protein was significantly decreased at 24 h after SAH. The SalA treatment, however, increased the expression of Nrf2. This indicated that SalA relieved lipid peroxidation and possibly restored the BBB function, by activating Nrf2 antioxidant-associated signaling pathways. A previous study also reported that SalA alleviated ischemic brain injury through the inhibition of inflammation of neurogenesis in mice [24-26]. In our study, we found that SalA also showed an anti-inflammatory effect against EBI after SAH in rats. The SAH-induced increase of pro-inflammatory cytokines, such as TNF-α, IL-1β, IL-6, and IL-8, was significantly reversed by SalA.

The MAPK signaling system, which is composed of ERK, JNK, and p38 MAPK [25, 26], up-regulates Nrf2 signaling. Generally, p38 MAPK and JNK pathways can be activated by genotoxic agents and cytokine-mediating stress responses, causing growth inhibition and apoptosis in cells. Cell apoptosis is closely associated with the activation of JNK and p38 MAPK signaling pathways and inactivation of the ERK signaling pathway, which is characterized by increased protein phosphorylation of p38 MAPK and/or JNK, and/or decreased protein phosphorylation of ERK [26, 27]. Therefore, we detected their phosphorylation levels using western blot analysis. SAH increased the phosphorylation of p38 MAPK and decreased the phosphorylation of ERK. These changes were reversed by SalA treatment. JNK phosphorylation was also increased in SAH group. However, the SalA treatment had no effect on the phosphorylation of JNK. This indicated that SalA attenuated EBI following SAH by regulating MAPK signaling (except the JNK signaling pathway).

In conclusion, this study indicated that intraperitoneal administration of SalA (10 and 50 mg/kg/day) confers protection against SAH-induced EBI in rats through the inhibition of oxidative stress and inflammation, and the promotion of BDNF production in vivo. The SAH treatment improved the neurobehavioral deficit, attenuated brain edema and BBB permeability, and reduced oxidative stress and cortical apoptosis. These finding suggested that SAH could be a potential candidate treatment for EBI after SAH.

Acknowledgements

This work is supported by Fujian medical university qihang fund (No. 2016HQ097).

Disclosure of conflict of interest

None.

Address correspondence to: Huabin Zhang, Department of Neurosurgery, Mindong Hospital Affiliated to Fujian Medical University, No.89 Heshan Road, Fuan 355000, P. R. China. Tel: +86 0593 6868512 Ext. 8268; Fax: +86 0593 6868512; E-mail: huabinzhang0806@126.com

References


[2] Madias JE. What could be the mechanism of the delayed normalization of the electrocardio-


SalA attenuates EBI after SAH in rats


